Noticias y Actividades de Jnana Therapeutics
Presencia
Fusión, adquisición y financiación con participación de Jnana Therapeutics.
- Otsuka Pharmaceutical has announced the acquisition of Jnana Therapeutics (publicado el 1 de agosto de 2024).
Ejecutivos
Ver el organigrama con sus 19 ejecutivos principales
Biografías más buscadas en Jnana Therapeutics
- Joanne Kotz, Director, President and Chief Executive Officer
- Annie Chen, Director
- Matthew Hammond, Director
Recientes movimientos de ejecutivos en Jnana Therapeutics
- Ron Renaud, Director, ha dejado la empresa (noticia publicada el 4 de octubre de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en Jnana Therapeutics.
Biotecnología
Jnana Therapeutics tiene 2.339 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Biogen (Estados Unidos).
Popular M&A news in Biotecnología
- Jade Biosciences and Aerovate Therapeutics have announced they will merge (publicado el 30 de abril de 2025)..
- Deepull acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 29 de abril de 2025).
- Biolinq acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 23 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Jnana Therapeutics
- News & Insights | Jnana Therapeutics
- Jnana Therapeutics to Present Preclinical Data for its PKU Program at the 2022 National PKU Alliance (NPKUA) Conference • Jnana Therapeutics
- Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer • Jnana Therapeutics
- Jnana Therapeutics Announces Promotion of Joel Barrish, Ph.D., to President and Chief Scientific Officer • Jnana Therapeutics
- Jnana Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference • Jnana Therapeutics
- Jnana Therapeutics Announces Appointment of John Throup, Ph.D. as Senior Vice President, Head of Development • Jnana Therapeutics
- Jnana Therapeutics to Advance JNT-517 as Development Candidate and Potential First-in-Class Oral Treatment for PKU • Jnana Therapeutics
- Jnana Therapeutics closes $50 million Series B financing to advance lead PKU program and small molecule pipeline based on next gen chemoproteomic platform • Jnana Therapeutics
- Jnana Therapeutics Expands Leadership Team with Two Experienced Biopharmaceutical Executives • Jnana Therapeutics
- Jnana Therapeutics Appoints Dr. Annie Chen to Board of Directors and Dr. Katalin Susztak to Scientific Advisory Board • Jnana Therapeutics
- View more press releases Close
Redes sociales sobre Jnana Therapeutics
- Jnana Therapeutics en Wikipedia, Google News y Yahoo Finance
- Jnana Therapeutics en LinkedIn, Twitter y YouTube
